Literature DB >> 28579006

Incremental shuttle walk test distance and autonomic dysfunction predict survival in pulmonary arterial hypertension.

Catherine G Billings1, Judith A Hurdman1, Robin Condliffe1, Charlie A Elliot1, Ian A Smith1, Matthew Austin1, Iain J Armstrong1, Neil Hamilton1, Athanasios Charalampopoulos1, Ian Sabroe2, Andrew J Swift3, Alexander M Rothman4, Jim M Wild3, Allan Lawrie4, Judith C Waterhouse1, David G Kiely5.   

Abstract

BACKGROUND: To ensure effective monitoring of pulmonary arterial hypertension (PAH), a simple, reliable assessment of exercise capacity applicable over a range of disease severity is needed. The aim of this study was to assess the ability of the incremental shuttle walk test (ISWT) to correlate with disease severity, measure sensitivity to change, and predict survival in PAH.
METHODS: We enrolled 418 treatment-naïve patients with PAH with baseline ISWT within 3 months of cardiac catheterization. Clinical validity and prognostic value of ISWT distance were assessed at baseline and 1 year.
RESULTS: ISWT distance was found to correlate at baseline with World Health Organization functional class, Borg score, and hemodynamics without a ceiling effect (all p < 0.001). Walking distance at baseline and after treatment predicted survival; the area under the receiver operating characteristic curve for ability of ISWT distance to predict mortality was 0.655 (95% confidence interval 0.553-0.757; p = 0.004) at baseline and 0.737 (95% confidence interval 0.643-0.827; p < 0.001) at 1 year after initiation of treatment. Change in ISWT distance also predicted survival (p = 0.04). Heart rate (HR) and systolic blood pressure (SBP) parameters reflecting autonomic response to exercise (highest HR, change in HR, HR recovery at 1 minute >18 beats/min, highest SBP, change in SBP, and 3-minute SBP ratio) were significant predictors of survival (all p < 0.05).
CONCLUSIONS: In patients with PAH, the ISWT is simple to perform, allows assessment of maximal exercise capacity, is sensitive to treatment effect, predicts outcome, and has no ceiling effect. Also, measures of autonomic function made post-exercise predict survival in PAH.
Copyright © 2017. Published by Elsevier Inc.

Entities:  

Keywords:  autonomic function; exercise testing; heart rate recovery; incremental shuttle walk test; prognosis; pulmonary arterial hypertension

Mesh:

Year:  2017        PMID: 28579006     DOI: 10.1016/j.healun.2017.04.008

Source DB:  PubMed          Journal:  J Heart Lung Transplant        ISSN: 1053-2498            Impact factor:   10.247


  10 in total

1.  Carotid chemoreflex activity restrains post-exercise cardiac autonomic control in healthy humans and in patients with pulmonary arterial hypertension.

Authors:  Marcelle Paula-Ribeiro; Indyanara C Ribeiro; Liliane C Aranda; Talita M Silva; Camila M Costa; Roberta P Ramos; Jaquelina S Ota-Arakaki; Sergio L Cravo; Luiz E Nery; Michael K Stickland; Bruno M Silva
Journal:  J Physiol       Date:  2019-01-30       Impact factor: 5.182

2.  Heart rate recovery in 1 minute after the 6-minute walk test predicts adverse outcomes in pulmonary arterial hypertension.

Authors:  Camila Farnese Rezende; Eliane Viana Mancuzo; Ricardo de Amorim Corrêa
Journal:  PLoS One       Date:  2022-05-27       Impact factor: 3.752

3.  Reply to Hou et al.: Can Magnetic Resonance Imaging Effectively Evaluate the Prognosis of Patients with Pulmonary Arterial Hypertension?

Authors:  Andrew J Swift; Jim M Wild; David G Kiely
Journal:  Am J Respir Crit Care Med       Date:  2018-03-01       Impact factor: 21.405

4.  Incremental Shuttle Walking Test Distance Is Reduced in Patients With Pulmonary Hypertension in World Health Organisation Functional Class I.

Authors:  Catherine G Billings; Robert Lewis; Iain J Armstrong; Judith A Hurdman; Ian A Smith; Matthew Austin; Charlie A Elliot; Athanasios Charalampopoulos; Ian Sabroe; Allan Lawrie; A A Roger Thompson; Robin Condliffe; David G Kiely
Journal:  Front Med (Lausanne)       Date:  2018-06-21

5.  The incremental shuttle walk test predicts mortality in non-group 1 pulmonary hypertension: results from the ASPIRE Registry.

Authors:  Catherine G Billings; Robert Lewis; Judith A Hurdman; Robin Condliffe; Charlie A Elliot; A A Roger Thompson; Ian A Smith; Matthew Austin; Iain J Armstrong; Neil Hamilton; Athanasios Charalampopoulos; Ian Sabroe; Andrew J Swift; Alexander M Rothman; Jim M Wild; Allan Lawrie; Judith C Waterhouse; David G Kiely
Journal:  Pulm Circ       Date:  2019 Apr-Jun       Impact factor: 3.017

6.  Exploring a physiotherapy well-being review to deliver community-based rehabilitation in patients with pulmonary hypertension.

Authors:  Carol Keen; Molly Hashmi-Greenwood; Janelle York; Iain J Armstrong; Karen Sage; David Kiely
Journal:  Pulm Circ       Date:  2019-11-05       Impact factor: 3.017

7.  Supervised pulmonary hypertension exercise rehabilitation (SPHERe): study protocol for a multi-centre randomised controlled trial.

Authors:  Gordon McGregor; Julie Bruce; Stuart Ennis; James Mason; Ranjit Lall; Chen Ji; Harbinder Sandhu; Kate Seers; Prithwish Banerjee; Alastair Canaway; Katie Booth; Stephanie J C Taylor; Elizabeth Robertson; Tamar Pincus; Sally Singh; David Fitzmaurice; Sarah Bowater; Paul Clift; Martin Underwood
Journal:  BMC Pulm Med       Date:  2020-05-19       Impact factor: 3.317

8.  Identification of Cardiac Magnetic Resonance Imaging Thresholds for Risk Stratification in Pulmonary Arterial Hypertension.

Authors:  Robert A Lewis; Christopher S Johns; Marcella Cogliano; David Capener; Euan Tubman; Charlie A Elliot; Athanasios Charalampopoulos; Ian Sabroe; A A Roger Thompson; Catherine G Billings; Neil Hamilton; Kathleen Baster; Peter J Laud; Peter M Hickey; Jennifer Middleton; Iain J Armstrong; Judith A Hurdman; Allan Lawrie; Alexander M K Rothman; Jim M Wild; Robin Condliffe; Andrew J Swift; David G Kiely
Journal:  Am J Respir Crit Care Med       Date:  2020-02-15       Impact factor: 21.405

9.  Maximal Exercise Testing Using the Incremental Shuttle Walking Test Can Be Used to Risk-Stratify Patients with Pulmonary Arterial Hypertension.

Authors:  Robert A Lewis; Catherine G Billings; Judith A Hurdman; Ian A Smith; Matthew Austin; Iain J Armstrong; Jennifer Middleton; Alexander M K Rothman; John Harrington; Neil Hamilton; Abdul G Hameed; A A Roger Thompson; Athanasios Charalampopoulos; Charlie A Elliot; Allan Lawrie; Ian Sabroe; Jim M Wild; Andrew J Swift; Robin Condliffe; David G Kiely
Journal:  Ann Am Thorac Soc       Date:  2021-01

Review 10.  Neurohormonal modulation in pulmonary arterial hypertension.

Authors:  Eva L Peters; Harm Jan Bogaard; Anton Vonk Noordegraaf; Frances S de Man
Journal:  Eur Respir J       Date:  2021-10-28       Impact factor: 16.671

  10 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.